Roflumilast is an orally active phosphodiesterase 4 inhibitor approved for use in chronic obstructive pulmonary disease. Roflumilast N-oxide (RNO) is the active metabolite of roflumilast and has a demonstrated antiinflammatory impact in vivo and in vitro. To date, the effect of RNO on the synthetic function of airway smooth muscle (ASM) cells is unknown. We address this herein and investigate the effect of RNO on b 2 -adrenoceptor-mediated, cAMPdependent responses in ASM cells in vitro, and whether RNO enhances steroid-induced repression of inflammation. RNO (0.001-1,000 nM) alone had no effect on AMP production from ASM cells, and significant potentiation of the long-acting b 2 -agonist formoterol-induced cAMP could only be achieved at the highest concentration of RNO tested (1,000 nM). At this concentration, RNO exerted a small, but not significantly different, potentiation of formoterol-induced expression of antiinflammatory mitogenactivated protein kinase phosphatase 1. Consequently, tumor necrosis factor-induced IL-8 secretion was unaffected by RNO in combination with formoterol. However, because there was the potential for phosphodiesterase 4 inhibitors and long-acting b 2 -agonists to interact with corticosteroids to achieve superior antiinflammatory efficacy, we examined whether RNO, alone or in combination with formoterol, enhanced the antiinflammatory effect of dexamethasone by measuring the impact on IL-8 secretion. Although RNO alone did not significantly enhance the cytokine repression achieved with steroids, RNO in combination with formoterol significantly enhanced the antiinflammatory effect of dexamethasone in ASM cells. This was linked to increased mitogen-activated protein kinase phosphatase 1 expression in ASM cells, suggesting that a molecular mechanism is responsible for augmented antiinflammatory actions of combination therapeutic approaches that include RNO.
Roflumilast N-oxide (RNO) is the active metabolite of roflumilast, a phosphodiesterase (PDE) 4 inhibitor that has been approved for the oral, once-daily treatment of severe chronic obstructive pulmonary disease (COPD) (1) . PDEs are an enzyme superfamily with considerable importance in chronic respiratory diseases (2) .
In particular, the PDE4 isoform is known to inactivate the major bronchodilatory second messenger, cAMP, and together with b 2 -agonists, PDE4 inhibitors can increase the amount of intracellular cAMP in airway smooth muscle (ASM) and can reverse bronchospasm. However, there has been an emerging appreciation of the antiinflammatory effects of these medicines (2, 3) that can also occur in a cAMPdependent manner (4) . Using primary cultures of ASM cells, we recently examined the ability of a panel of PDE4 inhibitors to enhance cAMP production in response to the long-acting b 2 -agonist (LABA) formoterol (5) . By increasing cAMP levels, PDE4 inhibitors, in combination with formoterol, inhibited proinflammatory cytokine production from ASM cells. This was caused by up-regulation of the cAMP-dependent, antiinflammatory protein-mitogen-activated protein kinase (MAPK) phosphatase 1 (MKP-1) (5) .
Roflumilast has been shown to be antiinflammatory in vitro and in vivo (reviewed in [6] ). It can have beneficial effects on its own in some experimental contexts (6) , but can have positive interactions especially with LABA-mediated impacts, interactions that may prove to be therapeutically advantageous (7) . To date, its effects on formoterol-induced cAMP production in ASM cells are unknown. Whether roflumilast acts on ASM cells in a manner similar that of other PDE4 inhibitors (cilomilast, piclamilast, rolipram) (5) warrants further investigation. Accordingly, in this study, we use the active metabolite of roflumilast responsible for .90% of the PDE4 inhibition (8) , RNO, and examine the impact on cAMP production in ASM cells over a range of RNO concentrations, in the absence and presence of a LABA (formoterol). We determine the effect on antiinflammatory MKP-1 protein production and whether RNO affects neutrophilchemoattractant cytokine IL-8 secretion from ASM cells. Finally, because there is the demonstrated potential of PDE4 inhibitors and LABAs to interact with corticosteroids to achieve superior antiinflammatory efficacy (4, 7), we explore combination therapies in vitro and show that RNO, in combination with formoterol, enhances the repression of tumor necrosis factor (TNF)-induced IL-8 by dexamethasone in ASM cells in a manner linked to MKP-1 up-regulation.
Materials and Methods

Cell Culture
Ethical approval for the use of human bronchi (from patients undergoing surgical resection for carcinoma or lung transplant donors) was provided by the human research ethics committee of the University of Sydney and the Sydney South West Area Health Service. ASM cells were processed using established methods (9) , and each experiment used a minimum of three different ASM primary cell lines.
Chemicals
RNO was provided by Takeda (Konstanz, Germany). Unless otherwise specified, all chemicals used in this study were purchased from Sigma-Aldrich (St. Louis, MO), except for TNF (R&D Systems, Minneapolis, MN).
cAMP Assay
Enzyme immunoassay was used to measure cAMP (cAMP EIA 581001; Cayman Chemical Co., Ann Arbor, MI).
MKP-1 mRNA Expression and Protein
Up-Regulation MKP-1 mRNA expression was quantitated by real-time reverse transcriptase-polymerase chain reaction and MKP-1 protein upregulation detected by Western blotting using methods outlined in our previous publication (5).
ELISAs IL-8 ELISAs were performed using kits from BD Biosciences Pharmingen (San Diego, CA).
Statistical Analysis
Statistical analysis was performed using Student's unpaired t test or one-way analysis of variance, and then Fisher's post hoc multiple comparison test. P values ,0.05 were sufficient to reject the null hypothesis for all analyses.
Results
Effect of RNO (0.001-1,000 nM) on Formoterol-Induced cAMP Production in ASM Cells RNO is an inhibitor of PDE4, and to determine whether it enhances b 2 -adrenoceptor mediated responses in ASM cells in a manner similar to that of other PDE4 inhibitors (specifically cilomilast, piclamilast, and rolipram [5] ), we examined the impact of pretreating ASM cells with a range of concentrations of RNO (0.001-1,000 nM) before stimulation with the LABA formoterol (10 nM). These experiments were performed alongside relevant controls, and as shown in Figure 1 , increasing concentrations of RNO added alone (0.001-1,000 nM) had no effect on cAMP production in the absence of b 2 -agonist stimulation. In contrast, formoterol significantly increased cAMP production in 
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ASM cells (in accordance with our earlier studies [5, 10] ), and this could be increased significantly by pretreatment with RNO at the highest concentration tested (i.e., 1,000 nM) ( Figure 1 ) (P , 0.05). Because RNO at 1,000 nM increases formoterol-induced cAMP production, we chose this concentration for further investigation.
Effect of RNO (1,000 nM) on Formoterol-Induced MKP-1 mRNA Expression and Protein Up-Regulation in ASM Cells
Our previous studies in ASM cells have confirmed that stimuli that increase cAMP induce expression of the cAMP-dependent antiinflammatory protein MKP-1 (5, (11) (12) (13) . Because RNO (at 1,000 nM) increased cAMP production in response to formoterol, we hypothesized that RNO would augment MKP-1 expression in response to the LABA in ASM cells. To test this, we pretreated ASM cells with 1,000 nM of RNO and examined the impact on formoterol-induced MKP-1 mRNA expression ( Figure 2A ) and MKP-1 protein up-regulation (Figures 2B and 2C), compared with relevant controls. Although formoterol induced MKP-1 mRNA and protein up-regulation, in accordance with our prior publications (5, 10-12), there was little impact of RNO on MKP-1 production. This is shown in Figure 2A , where although there was a small increase in formoterolinduced MKP-1 levels in the presence of 1,000 nM RNO, this was not significantly different from formoterol alone. Moreover, there was no significant increase in formoterol-induced MKP-1 protein upregulation, as shown by Western blotting ( Figure 2B ) or by densitometry ( Figure 2C ).
RNO (1,000 nM), Alone or in Combination with Formoterol, Does Not Repress TNF-Induced IL-8 Secretion MKP-1 is an antiinflammatory protein that can repress synthetic function of ASM cells (14-17) Thus, it follows that because RNO did not increase formoterolinduced MKP-1, it is unlikely that RNO will not increase the antiinflammatory capacity of formoterol in ASM cells. To confirm that this is indeed the case, we examined the impact of RNO (1,000 nM) and formoterol (10 nM), alone or in combination, on the secretion of the neutrophil chemoattractant IL-8 induced by TNF. As shown in Figure 3 , there was no effect of RNO and formoterol, alone or in combination, on unstimulated levels of IL-8. When cells were stimulated for 24 hours with TNF (resulting in secretion of 23,219.9 6 6,682.9 pg/ml IL-8 [mean 6 SEM]), formoterol alone did not repress IL-8 secretion, in confirmation of our earlier study (12) . Moreover, RNO (1,000 nM), alone or in combination with formoterol, did not repress TNF-induced IL-8 secretion ( Figure 3 ). with TNF, compared with vehicle control. IL-8 protein secretion was detected by ELISA and, as shown in Figure 4A , TNFinduced IL-8 secretion was inhibited by the corticosteroid dexamethasone (P , 0.05). Notably, the only combination that resulted in a significantly greater repression of cytokine production above that achieved by dexamethasone alone was that of RNO and formoterol (P , 0.05). RNO alone did not increase dexamethasone-mediated cytokine repression. To examine whether this was caused by an enhancement of MKP-1 upregulation under these conditions, MKP-1 protein was quantified by Western blotting. As shown in the representative Western blot ( Figure 4B ), MKP-1 protein levels were increased in cells treated with RNO plus formoterol plus dexamethasone, compared with TNF alone. This augmentation was shown to be significant by densitometric analysis (P , 0.05) ( Figure 4C ). Taken together, these results suggest that RNO (1,000 nM), in combination with formoterol, enhances the repression of TNF-induced IL-8 by dexamethasone in ASM cells in a manner linked to increased MKP-1 up-regulation.
Discussion
To the best of our knowledge, we are the first to examine the effect of RNO, the active metabolite of roflumilast, on cAMP production in ASM cells. We examined a range of RNO concentrations, and only the highest concentration used (i.e., 1,000 nM) had any significant effect on formoterol-induced cAMP. RNO alone did not increase cAMP production in ASM cells at any concentration examined. Given its relatively low efficacy as a cAMP-inducer in ASM cells, RNO (at 1,000 nM) only minimally increased formoterol-induced MKP-1 mRNA expression and protein up-regulation, and the impact was not significant. Consequently, TNF-induced IL- Over the past decade, our in vitro studies have underscored the important role played by the MAPK deactivator MKP-1 in controlling airway inflammation in experimental models of chronic respiratory disease. We have delineated the molecular mechanisms underlying MKP-1 up-regulation and confirmed its nature as an immediate early response gene (18) containing cAMP-responsive (19, 20) and novel glucocorticoid-responsive elements (21) within its 59-untranslated region, by showing that MKP-1 can be upregulated by agents that stimulate cAMP in ASM cells (dibutyrl cAMP [22] , forskolin [22] , sphingosine 1-phosphate [22] , prostaglandin E 2 [13] , and LABAs [formoterol (5, 10-12), salmeterol (12)]), as well as by steroids (dexamethasone [11, 14] , fluticasone [12, 14] ). Together, cAMPelevating agents and steroids can act in an additive manner to increase MKP-1 up-regulation, and we have shown this with steroids and LABA added in combination (11, 12) .
More recently, we have shown that PDE4 inhibitors, but not PDE3 inhibitors, can also increase MKP-1, in a manner dependent on their ability to increase cAMP (5) . Herein, we examined RNO, the active metabolite of the orally active PDE4 inhibitor roflumilast, and examined its impact on cAMP production, alone and in combination with formoterol. A broad concentration range was tested (0.001-1,000 nM) because RNO is PDE4 selective over this range. Notably, RNO had no effect on its own. When added with formoterol, RNO could significantly increase formoterolinduced cAMP only at the highest concentration tested (1,000 nM). Consequently, there was only a small but not statistically significant effect on formoterol-induced MKP-1 mRNA and protein up-regulation. We do know, however, that there is a cAMP dose-dependency aspect to MKP-1 expression that was demonstrated recently because PGE 2 (a cAMP-elevating agent in ASM cells [23] ) increases MKP-1 mRNA expression in a concentration-dependent manner (13) .
Thus, when we tested the impact of RNO plus formoterol on the secretion of IL-8 in response to TNF, there was no antiinflammatory impact. Given that we have previously shown an additive effect of cAMP-elevating agents with corticosteroids on MKP-1 up-regulation (11, 12) , we were intrigued to examine whether RNO in combination with formoterol increases the antiinflammatory impact of dexamethasone on TNF-induced IL-8 in ASM cells. Indeed, this was the case, and although RNO alone did not significantly enhance the cytokine repression achieved with steroids, RNO in combination with formoterol significantly enhanced the antiinflammatory effect of dexamethasone in ASM cells. Collectively, the weight of previous evidence strongly suggests that the antiinflammatory effects of RNO are a result of increased MKP-1 up-regulation. However, in this experimental context, it is not possible to directly demonstrate MKP-1 dependence. To do this, two experimental approaches could be used (pharmacological inhibitors of MKP-1 or small interfering RNA [siRNA] against MKP-1), but unfortunately, both have well-documented limitations. First, one could use triptolide, the most commonly used pharmacological inhibitor of MKP-1 (24) . We have used triptolide previously to block MKP-1 upregulation and to demonstrate that MKP-1 restrains downstream MAPK signaling (15). But triptolide is a nonspecific inhibitor and has other targets apart from MKP-1 (25) ; notably, these include nuclear factorkB (NF-kB). Because TNF-induced IL-8 production in ASM cells is NF-kB dependent (26), it is not possible to use triptolide to inhibit MKP-1 and demonstrate the involvement of MKP-1 in the impact of RNO plus formoterol on the TNF-induced IL-8 production. Second, MKP-1 can be knocked down with siRNA. But this approach cannot give clear-cut answers, because as we have reported previously (12) , MKP-1 is in an interdependent ying-yang relationship with another antiinflammatory protein, tristetraprolin (TTP). TTP is an antiinflammatory protein that induces the decay of mRNAs encoding several cytokines, including those that drive COPD pathogenesis, including IL-8 (27) .
Expression and function of TTP is highly regulated and is amenable to rapid control in a mechanism akin to an on-off molecular switch. Importantly, it is controlled by p38 MAPK, its expression is p38 MAPK dependent (28) , and its mRNA destabilizing function is controlled by p38 MAPK/MK2-mediated phosphorylation on two key serine residues (S52 and S178), preventing the initiation of mRNA decay (29) . We and others have underscored the importance of the MKP-1/p38/TTP regulatory network in the control of cytokine expression in vivo in MKP-1 and TTP transgenic mice (30, 31) and in vitro (16, 17, 32, 33) . Thus, when we knock down MKP-1 with siRNA, we cannot predict that we will observe an increase in cytokine production. This is because MKP-1 and TTP are intimately linked to control inflammatory pathways in a p38 MAPK-dependent manner. Importantly, the cytokine regulatory network controlled by MKP-1/TTP ensures that proinflammatory cellular signaling can be switched on and switched off at the precisely the right time.
Conclusions
To the best of our knowledge, this report represents the first study to examine the impact of RNO on ASM cells, although other cell types have been used in previous publications (reviewed in [6, 7] ). Milara and colleagues (34, 35) have demonstrated the influence of RNO in improving the effect of corticosteroids. In bronchial epithelial cells from patients with COPD, RNO, when combined with dexamethasone, increased the expression of MKP-1 and enhanced the inhibitory effects on phospho-p38 MAPK and the activity of transcription factors AP-1 and NF-kB (35) . In addition, Milara and colleagues (35) found that in neutrophils from patients with COPD, RNO in combination with dexamethasone had an additive/synergistic antiinflammatory effect. Moodley and colleagues (36) have used lung epithelial cells and primary cultures to demonstrate that PDE4 inhibitors (including roflumilast) augment the ability of formoterol to enhance transcriptional regulation (glucocorticoid response element luciferase reporter activity) induced by steroids. Via a glucocorticoid response element-dependent molecular mechanism, roflumilast interacted with formoterol in a positive manner to enhance glucocorticoid-dependent transcription of antiinflammatory genes, including GILZ and RGS2 (36) . Although the gene for MKP-1 (DUSP1) was not examined in the study, our data concur with those from the Giembycz group (Moodley and colleagues [36] ) because they support the concept that "these drugs together may impart clinical benefit beyond that achievable by an ICS alone, a PDE4 inhibitor alone, or an ICS/LABA combination therapy". Although our in vitro experimental model of airway inflammation does not fully encapsulate the complexity of COPD, these studies, taken together, provide a molecular mechanism that may explain the benefits of adding roflumilast as an "add-on" therapy in severe COPD, for which patients are likely taking LABAs and inhaled corticosteroids. n Author disclosures are available with the text of this article at www.atsjournals.org.
